CN100387271C - Medicine for treating hepatitis B - Google Patents
Medicine for treating hepatitis B Download PDFInfo
- Publication number
- CN100387271C CN100387271C CNB2004100604262A CN200410060426A CN100387271C CN 100387271 C CN100387271 C CN 100387271C CN B2004100604262 A CNB2004100604262 A CN B2004100604262A CN 200410060426 A CN200410060426 A CN 200410060426A CN 100387271 C CN100387271 C CN 100387271C
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- present
- treating hepatitis
- spleen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title description 3
- 241000190633 Cordyceps Species 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 9
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 5
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 5
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 5
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 5
- 241000222640 Polyporus Species 0.000 claims description 5
- 229940100243 oleanolic acid Drugs 0.000 claims description 5
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 10
- 210000000952 spleen Anatomy 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 206010023126 Jaundice Diseases 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 102000014150 Interferons Human genes 0.000 abstract description 2
- 108010050904 Interferons Proteins 0.000 abstract description 2
- 229940079322 interferon Drugs 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 235000014493 Crataegus Nutrition 0.000 abstract 1
- 241001092040 Crataegus Species 0.000 abstract 1
- 241000594394 Hedyotis Species 0.000 abstract 1
- 241001662043 Icterus Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000171085 Polyporus umbellatus Species 0.000 abstract 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- -1 biphenyl diester Chemical class 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 4
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to traditional Chinese medicine for treating hepatitis B, which is prepared from the following ingredients by weight parts: 50 parts of pigs' gallbladder powder, 25 parts of polyporus umbellatus, 15 parts of oleaolic acid, 5 parts of biphenyl diester and 5 parts of cordyceps. The following ingredients by weight parts can also be added to the raw material: 40 parts of herba hedyotis, 30 parts of rhizoma polygoni cuspidati, 15 parts of wolfberry fruits, 15 parts of rhizoma atractylodis macrocephalae and 15 parts of hawthorns. The present invention has the combined functions of strong antiviral capacity, immunity enhancement, spleen and stomach strengthening, the activation of blood circulation, the dissipation of blood stasis, spleen and stomach nourishing, icterus withdrawal and enzyme reduction. A total effective rate is 95%, and the present invention has better effects than those of other medicine for treating hepatitis B comprising interferon after patients take the medicine for three treatment courses.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of hepatitis B.
Background technology
Hepatitis B is that a kind of infectiousness is strong, and up to the present the difficult and complicated illness that sickness rate is high does not also have specific drug can treat recovery from illness.Hepatitis B further develops, and can be converted into hepatic injury, liver cirrhosis, hepatic ascites or hepatocarcinoma.The origin cause of formation of hepatitis B mainly is that hepatitis B virus duplicates in liver for a long time, has destroyed the normal physiological state of liver, and then has developed into hepatitis.Pulvis Fellis Suis has stronger heat-clearing and toxic substances removing, the effect of jaundice eliminating, Polyporus also has the effect of antiviral, invigorating spleen for diuresis, Cordyceps has the function that increases immunity, oleanolic acid also has the effect of invigorating the liver and kidney, bifendate has the effect of blood fat reducing, and Herba Hedyotidis Diffusae, Rhizoma Polygoni Cuspidati, fructus lycii, the Rhizoma Atractylodis Macrocephalae, Fructus Crataegi have the effect of heat-clearing and toxic substances removing, activating blood circulation to dissipate blood stasis, invigorating the liver and kidney, strengthening the spleen and stomach.At present, the curative effect of medication of existing treatment hepatitis B is all bad, and in Chinese medicine preparation, often of a great variety because of heat-clearing and toxic substances removing is difficult to select, and causes the effect of treatment by Chinese herbs hepatitis B poor equally.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art and the medicine of a kind of good effect, relapse rate is low, side effect is little treatment hepatitis B is provided.
The object of the present invention is achieved like this: formulated by weight by following composition: 50 parts of Pulvis Fellis Suiss, 25 parts of Polyporus, 15 parts of oleanolic acid, 5 parts of bifendates, 5 parts of Cordyceps.It is formulated by weight to add following composition in above-mentioned composition: 40 parts of Herba Hedyotidis Diffusaes, 30 parts of Rhizoma Polygoni Cuspidati, 15 parts of fructus lyciis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Fructus Crataegis.
The comprehensive function that the present invention has that antiviral strength is strong, enzyme falls in raise immunity, strengthening the spleen and stomach, activating blood circulation to dissipate blood stasis, tonifying the spleen and stomach, jaundice eliminating subcutaneous ulcer.The present invention treats 102 routine hepatitis B virus carrierss, and total effective rate reaches 95%, and the surface antigen negative conversion rate encloses 40%, and center antigen negative conversion rate is 25%, takes three the present invention's course of treatment and has surpassed other any hepatitis B medicine that comprises interferon.
The specific embodiment
Embodiment 1: it is formulated to select for use following composition to restrain number by weight: Pulvis Fellis Suis 5 grams, Polyporus 2.5 grams, oleanolic acid 1.5 grams, bifendate 0.5 gram, Cordyceps 0.5 gram, after above-mentioned composition can being pulverized with pulverizer, incapsulate and take, adult every day 3 times, 5 of every days.
Embodiment 2: can also further adding following composition in above-mentioned composition, to restrain number by weight formulated: Pulvis Fellis Suis 5 grams, Polyporus 2.5 grams, oleanolic acid 1.5 grams, bifendate 0.5 gram, Cordyceps 0.5 gram, Herba Hedyotidis Diffusae 4 grams, Rhizoma Polygoni Cuspidati 3 grams, fructus lycii 1.5 grams, the Rhizoma Atractylodis Macrocephalae 1.5 grams, Fructus Crataegi 1.5 grams, after above-mentioned composition can being pulverized with pulverizer, incapsulate and take, adult every day 3 times, 5 of every days.
Claims (1)
1. a medicine for the treatment of hepatitis B is characterized in that: formulated by weight by following composition: 50 parts of Pulvis Fellis Suiss, 25 parts of Polyporus, 15 parts of oleanolic acid, 5 parts of bifendates, 5 parts of Cordyceps, 40 parts of Herba Hedyotidis Diffusaes, 30 parts of Rhizoma Polygoni Cuspidati, 15 parts of fructus lyciis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Fructus Crataegis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100604262A CN100387271C (en) | 2004-07-26 | 2004-07-26 | Medicine for treating hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100604262A CN100387271C (en) | 2004-07-26 | 2004-07-26 | Medicine for treating hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1586617A CN1586617A (en) | 2005-03-02 |
| CN100387271C true CN100387271C (en) | 2008-05-14 |
Family
ID=34603452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100604262A Expired - Fee Related CN100387271C (en) | 2004-07-26 | 2004-07-26 | Medicine for treating hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100387271C (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Anti- hepatitis B preparation |
| CN1163143A (en) * | 1997-05-05 | 1997-10-29 | 徐相廷 | Medicine powder for curing hepatitis B |
| CN1336233A (en) * | 2001-08-28 | 2002-02-20 | 王旭中 | Hepatitis B treating medicine |
-
2004
- 2004-07-26 CN CNB2004100604262A patent/CN100387271C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Anti- hepatitis B preparation |
| CN1163143A (en) * | 1997-05-05 | 1997-10-29 | 徐相廷 | Medicine powder for curing hepatitis B |
| CN1336233A (en) * | 2001-08-28 | 2002-02-20 | 王旭中 | Hepatitis B treating medicine |
Non-Patent Citations (4)
| Title |
|---|
| 中医中药诊治乙型病毒性肝炎述评. 匡奕璜.江西中医药，第28卷第1期. 1997 |
| 中医中药诊治乙型病毒性肝炎述评. 匡奕璜.江西中医药，第28卷第1期. 1997 * |
| 中药煎剂治疗慢性乙型肝炎临床研究进展. 李惠义等.中医药研究，第18卷第4期. 2002 |
| 中药煎剂治疗慢性乙型肝炎临床研究进展. 李惠义等.中医药研究，第18卷第4期. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1586617A (en) | 2005-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1286518C (en) | Chinese medicinal prescription for treating gastropathy | |
| CN101284101A (en) | Chinese traditional medicine for curing fatty liver and hyperlipemia | |
| CN102872414A (en) | Bupleurum capsule group for relieving depression | |
| CN103142920A (en) | Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof | |
| CN1840147A (en) | Tibet medicine for resisting virus, eliminating inflammation and expelling toxin | |
| CN1063954C (en) | Chinese patent medicine-powder preparation for curing hepatitis B | |
| CN100387271C (en) | Medicine for treating hepatitis B | |
| CN102813855B (en) | Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN104258305A (en) | Traditional Chinese medicine preparation for treating chronic liver and gall diseases | |
| CN1931331A (en) | Chinese medicine composition for treating hepatitis B and its prepn process | |
| CN103656226A (en) | Compound medicine for treating sicca syndrome | |
| CN101837049A (en) | Chinese composition and preparation method and application thereof | |
| CN102670962A (en) | Combined tablet capable of soothing liver and relieving depression | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN101301382B (en) | Externally used Chinese medicine for treating viral hepatitis jaundice and preparation thereof | |
| CN103893566A (en) | Giant salamander Chinese herbal medicine compound preparation for treating hepatitis B | |
| CN1086132C (en) | Traditional Chinese medicinal pill for transforming calculus, eliminating toxin and anti tumour | |
| CN102085272A (en) | Traditional Chinese medicine for treating hepatitis B | |
| CN1286483C (en) | Chinese traditional drug pills capable of protecting liver, resisting hepatic fibrosis and expelling toxins | |
| CN1092970C (en) | Compound Chinese medicine for treating hepatocholepathy | |
| CN1279074A (en) | Chinese-medicinal pill 'Ganxuetong' | |
| CN101642541A (en) | Composition with hepatoprotective effect, preparation method and application thereof | |
| CN100591353C (en) | A kind of traditional Chinese medicine preparation for treating hepatitis and preparation method thereof | |
| CN106377712A (en) | Traditional Chinese medicine for treating hepatitis C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080514 Termination date: 20100726 |